Recently, clinical studies have shown that the aberrant expression of TIMP1 is associated with an unfavorable prognosis in a series of tumors, such as gastric cancer [12], papillary thyroid carcinoma [13], cutaneous melanoma [14] and breast cancer [8]. This evidence concerns the gene TIMP1 and breast cancer.